Guideline Alignment and Medication Concordance in COPD

Meredith A. Case MD, MHS , Eric P. Boorman PhD , Elizabeth Ruvalcaba MSPH , Michael T. Vest DO , Nadia N. Hansel MD, MPH , Nirupama Putcha MD, MHS , Michelle N. Eakin PhD
{"title":"Guideline Alignment and Medication Concordance in COPD","authors":"Meredith A. Case MD, MHS ,&nbsp;Eric P. Boorman PhD ,&nbsp;Elizabeth Ruvalcaba MSPH ,&nbsp;Michael T. Vest DO ,&nbsp;Nadia N. Hansel MD, MPH ,&nbsp;Nirupama Putcha MD, MHS ,&nbsp;Michelle N. Eakin PhD","doi":"10.1016/j.chpulm.2023.100017","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Provider adherence to clinical treatment guidelines in COPD is low. However, for patients to receive guideline-aligned care, providers not only must prescribe guideline-aligned care, but also must communicate that regimen successfully to patients to ensure medication concordance. The rate of medication concordance between patients and providers and its impact on clinical management is unknown in COPD.</p></div><div><h3>Research Question</h3><p>To examine rates of guideline alignment and medication concordance and to identify patient-level factors that place patients at risk for these types of poor disease management outcomes.</p></div><div><h3>Study Design and Methods</h3><p>This study was a secondary data analysis of the Medication Adherence Research in COPD study (2017-2023). Participants were categorized into 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage. Medication regimens were classified as aligned or nonaligned with 2017 GOLD guidelines. Nonaligned regimens were stratified further into overuse and underuse categories. Medication concordance between provider-reported and participant-reported regimens was determined. Factors associated with guideline alignment and medication concordance were evaluated using logistic regression.</p></div><div><h3>Results</h3><p>Of 191 participants, 51% of provider-reported regimens were guideline aligned, with 86% of nonaligned regimens reflecting overuse with an inhaled corticosteroid (ICS). Thirty-eight percent of participants reported different regimens than their providers, of which &gt; 80% reflected participants not reporting medications their providers reported prescribing. Participants did not report long-acting muscarinic antagonists and long-acting beta-agonists at similar rates as ICSs. Greater symptom burden and absence of a pulmonologist on the care team were associated with both guideline misalignment and medication discordance. Cognitive impairment and Black race additionally were associated with medication discordance.</p></div><div><h3>Interpretation</h3><p>Guideline misalignment and medication discordance were common and were driven by overuse of ICSs and unreported medications, respectively. The patient-level factors associated with medication discordance highlight the importance of improving patient-provider communication to improve clinical management in COPD.</p></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S294978922300017X/pdfft?md5=28678bcf29fd4fa96c270a415bf9106b&pid=1-s2.0-S294978922300017X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CHEST pulmonary","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S294978922300017X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Provider adherence to clinical treatment guidelines in COPD is low. However, for patients to receive guideline-aligned care, providers not only must prescribe guideline-aligned care, but also must communicate that regimen successfully to patients to ensure medication concordance. The rate of medication concordance between patients and providers and its impact on clinical management is unknown in COPD.

Research Question

To examine rates of guideline alignment and medication concordance and to identify patient-level factors that place patients at risk for these types of poor disease management outcomes.

Study Design and Methods

This study was a secondary data analysis of the Medication Adherence Research in COPD study (2017-2023). Participants were categorized into 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage. Medication regimens were classified as aligned or nonaligned with 2017 GOLD guidelines. Nonaligned regimens were stratified further into overuse and underuse categories. Medication concordance between provider-reported and participant-reported regimens was determined. Factors associated with guideline alignment and medication concordance were evaluated using logistic regression.

Results

Of 191 participants, 51% of provider-reported regimens were guideline aligned, with 86% of nonaligned regimens reflecting overuse with an inhaled corticosteroid (ICS). Thirty-eight percent of participants reported different regimens than their providers, of which > 80% reflected participants not reporting medications their providers reported prescribing. Participants did not report long-acting muscarinic antagonists and long-acting beta-agonists at similar rates as ICSs. Greater symptom burden and absence of a pulmonologist on the care team were associated with both guideline misalignment and medication discordance. Cognitive impairment and Black race additionally were associated with medication discordance.

Interpretation

Guideline misalignment and medication discordance were common and were driven by overuse of ICSs and unreported medications, respectively. The patient-level factors associated with medication discordance highlight the importance of improving patient-provider communication to improve clinical management in COPD.

慢性阻塞性肺病的指南调整和用药一致性
背景慢性阻塞性肺病的临床治疗指南对医疗服务提供者的依从性很低。然而,要使患者接受与指南一致的治疗,医疗服务提供者不仅必须开具与指南一致的处方,还必须成功地将治疗方案传达给患者,以确保用药一致。在慢性阻塞性肺病中,患者与医疗服务提供者之间的用药一致性率及其对临床管理的影响尚不清楚。研究问题研究指南一致性率和用药一致性率,并确定使患者面临这类不良疾病管理结果风险的患者层面因素。研究设计和方法本研究是对慢性阻塞性肺病用药依从性研究(2017-2023 年)的二次数据分析。参与者被分为 2017 年慢性阻塞性肺病全球倡议(GOLD)阶段。药物治疗方案被分为与 2017 年 GOLD 指南一致或不一致。不一致的治疗方案进一步分为过度使用和使用不足两类。确定了提供者报告的用药方案与参与者报告的用药方案之间的一致性。结果 在 191 名参与者中,51% 的提供者报告的治疗方案与指南一致,86% 的非一致治疗方案反映出过度使用吸入式皮质类固醇 (ICS)。38% 的参与者报告的治疗方案与其提供者不同,其中 80% 反映出参与者未报告其提供者报告的处方药物。参与者报告的长效毒蕈碱拮抗剂和长效乙型受体激动剂的比例与 ICS 相似。更大的症状负担和护理团队中没有肺科医生与指南不一致和用药不一致有关。认知障碍和黑人种族也与用药不一致有关。释义指南不一致和用药不一致很常见,分别由过度使用 ICSs 和未报告用药引起。与用药不一致相关的患者层面因素凸显了加强患者与医护人员沟通以改善慢性阻塞性肺病临床管理的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信